. Inhibition of sustained smooth muscle contraction by PKA and PKG preferentially mediated by phosphorylation of RhoA. Am J Physiol Gastrointest Liver Physiol 284: G1006-G1016, 2003; 10.1152/ajpgi.00465.2002.-The role of RhoA in myosin light-chain (MLC) 20 dephosphorylation and smooth muscle relaxation by PKA and PKG was examined in freshly dispersed and cultured smooth muscle cells expressing wild-type RhoA, constitutively active Rho V14 , and phosphorylation site-deficient Rho A188 . Activators of PKA (5,6-dichloro-1-␤-ribofuranosyl benzimidazole 3Ј,5Ј-cyclic monophosphothionate, Sp-isomer; cBIMPS) or PKG [8-(4-chlorophenylthio)guanosine 3Ј,5Ј-cyclic monophosphate (8-pCPT-cGMP), sodium nitroprusside (SNP)] or both PKA and PKG (VIP) induced phosphorylation of constitutively active Rho V14 and agonist (ACh)-or GTP␥S-stimulated wild-type RhoA but not Rho A188 . Phosphorylation was accompanied by translocation of membrane-bound wild-type RhoA and Rho V14 to the cytosol and complete inhibition of AChstimulated Rho kinase and phospholipase D activities, RhoA/ Rho kinase association, MLC 20 phosphorylation, and sustained muscle contraction. Each of these events was blocked depending on the agent used, by the PKG inhibitor KT5823 or the PKA inhibitor myristoylated PKI. Inhibitors were used at a concentration (1 M) previously shown by direct measurement of kinase activity to selectively inhibit the corresponding kinase. In muscle cells overexpressing the active phosphorylation site-deficient mutant Rho A188 , MLC20 phosphorylation was partly inhibited by SNP, VIP, cBIMPS, and 8-pCPT-cGMP, suggesting the existence of an independent inhibitory mechanism downstream of RhoA. Results demonstrate that dephosphorylation of MLC 20 and smooth muscle relaxation are preferentially mediated by PKG-and PKAdependent phosphorylation and inactivation of RhoA. myosin light chain; myosin light chain phosphatase; regulatory myosin light chain; relaxation CONTRACTION OF VASCULAR AND visceral smooth muscle is mediated by phosphorylation of Ser 19 on the regulatory myosin light chain (MLC) 20 (14, 32) and consists of a transient initial phase followed by a prolonged, sustained phase. The initial phase is mediated by inositol 1,4,5-trisphosphate [Ins(1,4,5)P 3 ]-dependent Ca 2ϩ release and Ca 2ϩ /calmodulin-dependent activation of MLC kinase (14, 23, 32) . The sustained phase is RhoA dependent and reflects inhibition of MLC phosphatase (6, 32). On activation, RhoA is translocated to the membrane in which it initiates two converging pathways involving activation of Rho kinase and phospholipase D (PLD) (7, 22, 27) . Rho kinase inhibits MLC phosphatase via phosphorylation of the 130-kDa regulatory myosin phosphatase targeting subunit-1 (MYPT1) (6, 8, 32, 35) . Hydrolysis of phosphatidylcholine by PLD yields phosphatidic acid, which is dephosphorylated to diacylglycerol, leading to activation of PKC; PKC phosphorylates an endogenous 17-kDa inhibitory protein (CPI-17) which binds directly to and strongly inhibits MLC phosphatase (3, 20, 27) .
CONTRACTION OF VASCULAR AND visceral smooth muscle is mediated by phosphorylation of Ser 19 on the regulatory myosin light chain (MLC) 20 (14, 32) and consists of a transient initial phase followed by a prolonged, sustained phase. The initial phase is mediated by inositol 1,4,5-trisphosphate [Ins(1,4,5)P 3 ]-dependent Ca 2ϩ release and Ca 2ϩ /calmodulin-dependent activation of MLC kinase (14, 23, 32) . The sustained phase is RhoA dependent and reflects inhibition of MLC phosphatase (6, 32) . On activation, RhoA is translocated to the membrane in which it initiates two converging pathways involving activation of Rho kinase and phospholipase D (PLD) (7, 22, 27) . Rho kinase inhibits MLC phosphatase via phosphorylation of the 130-kDa regulatory myosin phosphatase targeting subunit-1 (MYPT1) (6, 8, 32, 35) . Hydrolysis of phosphatidylcholine by PLD yields phosphatidic acid, which is dephosphorylated to diacylglycerol, leading to activation of PKC; PKC phosphorylates an endogenous 17-kDa inhibitory protein (CPI-17) which binds directly to and strongly inhibits MLC phosphatase (3, 20, 27) .
Relaxation of the initial or sustained phase of contraction is mediated by dephosphorylation of Ser 19 on MLC 20 by the catalytic subunit of MLC phosphatase (21, 37) . Relaxant agonists inhibit smooth muscle contraction by activating cAMP-and/or cGMP-dependent protein kinase (PKA and PKG) (1, 15, 21, 29, 34) . Low levels of cAMP activate PKA exclusively, whereas higher levels can cross-activate PKG-I (12, 13, 24) . When both cyclic nucleotides are generated concurrently, for example, in response to VIP, cAMP activates PKA as well as PKG (24) . PKA and PKG inhibit the initial contraction by acting on two critical targets involved in Ca 2ϩ mobilization. Both protein kinases inhibit PLC-␤1-dependent Ins(1,4,5)P 3 formation by phosphorylating RGS-4 and accelerating the inactivation of GTP-bound G␣ q (28) . Only one kinase, PKG-I, inhibits Ins(1,4,5)P 3 -induced Ca 2ϩ release by direct phosphorylation of the sarcoplasmic Ins(1,4,5)P 3 receptor/Ca 2ϩ channel (16, 21) . Mechanisms invoked for relaxation of sustained contraction involve stimulation of MLC phosphatase activity via inhibition of RhoA and/or RhoA-dependent targets, such as MYPT1 and CPI-17 by PKG and/or PKA. Indirect evidence (30) suggests that PKG induces relaxation by phosphorylating RhoA: contraction of permeabilized vascular myocytes by exogenous geranylgeranylated RhoA was inhibited by exogenous PKG-I and 8-bromo-guanosine 3Ј,5Ј-cyclic monophosphate (8-Br-cGMP), whereas contraction by a RhoA mutant (Rho A188 ) that is not susceptible to phosphorylation by PKG was not affected, suggesting the absence of a mechanism of relaxation downstream of RhoA.
Inhibition of histamine-stimulated contraction and MLC 20 phosphorylation by PKG is accompanied by a decrease in CPI-17 phosphorylation that parallels the increase in MLC phosphatase activity, consistent with inhibition of RhoA activity upstream of the PLD/PKC/ CPI-17 pathway (4). However, there is also evidence that PKG stimulates MLC phosphatase activity independently of RhoA (32, 37) . The NH 2 -terminal zipper sequence of PKG-I␣ binds selectively to and induces phosphorylation of MYPT1. In vitro studies (32) suggest that this phosphorylation has no effect on MLC phosphatase activity; however, blockade of PKG-I␣ binding to MYPT1 prevented MLC 20 dephosphorylation by 8-Br-cGMP. Phosphorylation of Thr 850 in the COOH terminus of MYPT1 by PKA has been demonstrated in vitro only and appears to be associated with an increase in MLC phosphatase activity that could lead to MLC 20 dephosphorylation and relaxation (10, 11) .
In the present study, we examined the ability of both PKA and PKG to phosphorylate RhoA in freshly dispersed and cultured smooth muscle cells and determined the effect of this phosphorylation on agoniststimulated RhoA, Rho kinase, and PLD activities and on RhoA translocation to the cytosol and dissociation from membrane-bound Rho kinase. Parallel studies were done in cultured smooth muscle cells expressing GTPase-resistant, constitutively active Rho V14 to distinguish the effects of RhoA inactivation and translocation and in cells expressing phosphorylation sitedeficient Rho A188 to identify the effects of PKG and PKA on targets downstream of RhoA. The results showed that both kinases phosphorylate wild-type RhoA, stimulate its translocation back to the cytosol, and inhibit its activity and the activity of membranebound Rho kinase and PLD at the same time as they inhibited sustained MLC 20 phosphorylation and muscle contraction. In smooth muscle cells expressing Rho A188 , MLC 20 phosphorylation was significantly inhibited by PKG and PKA in the absence of RhoA phosphorylation, suggesting the existence of a subsidiary mechanism of relaxation downstream of RhoA.
MATERIALS AND METHODS

Preparation of dispersed gastric smooth muscle cells.
Smooth muscle cells were isolated from the circular muscle layer of rabbit stomach by sequential enzymatic digestion, filtration, and centrifugation as described previously (23) (24) (25) (26) . The partly digested strips were washed, and muscle cells were allowed to disperse spontaneously for 30 min. Cells were harvested by filtration through 500 m Nitex and centrifuged twice at 350 g for 10 min. For some experiments, the cells were cultured in DMEM containing 10% fetal bovine serum until they attained confluence and were then passaged once for use in various studies (27) .
Expression of dominant-negative Rho N19 , constitutively active Rho V14 , and phosphorylation site-deficient Rho A188 in cultured smooth muscle cells. RhoA mutant cDNA was subcloned into the multiple cloning site (EcoRI) of the eukaryotic expression vector (pEXV), and a myc tag was incorporated into the NH 2 terminus. Recombinant plasmid cDNAs (2 g each) were transiently transfected into cultured smooth muscle cells using Lipofectamine Plus reagent. The cells were cotransfected with 1 g of pGreen Lantern-1 DNA to monitor expression. Control cells were cotransfected with 2 g of pEXV and 1 g of pGreen Lantern-1 DNA. Transfection efficiency was monitored by the expression of green fluorescent protein using FITC filters. Expression was demonstrable in over 80% of the cells.
Phosphorylation of RhoA. Phosphorylation of RhoA was measured from the amount of 32 P incorporated into the enzyme after immunoprecipitation with specific RhoA antibody. Smooth muscle cell suspensions (10 ml; 3 ϫ 10 6 cells/ ml) were incubated with [ 32 P]orthophosphate for 4 h at 31°C. One-milliliter samples were then incubated with various agents for 1 min in the presence or absence of specific PKA or PKG inhibitors. The reaction was terminated with an equal volume of lysis buffer (final concentrations in mM: 150 NaCl, 10 MgCl 2, 1 PMSF, 10 EDTA, 10 Na2P2O7, 50 NaF, 0.2 Na 3VO4, plus 1% Triton X-100, 0.5% SDS, 0.75% deoxycholate, 10 g/ml leupeptin, and 100 g/ml aprotinin). The cell lysates were separated by centrifugation at 13,000 g for 15 min at 4°C, and they were incubated with polyclonal RhoA antibody for 2 h at 4°C and with 40 l of protein A-Sepharose for another 1 h. The immunoprecipitates were washed, extracted with Laemmli buffer, and separated by electrophoresis on 10% SDS-PAGE. After transfer to polyvinylidine difluoride membranes, 32 P-labeled RhoA was visualized by autoradiography, and the amount of radioactivity in the band was measured by liquid scintillation and expressed as counts/min (cpm)/mg protein.
Assay for activated RhoA. Activated RhoA was measured in freshly dispersed or cultured muscle cells incubated for 3 h in low-phosphate medium containing 10 mCi 32 PO4 as described previously (27) . Aliquots (2 ϫ 10 6 cells) were treated with ACh in the presence or absence of PKA and PKG activators, and lysates were prepared. RhoA was immunoprecipitated with RhoA antibody in freshly dispersed cells with myc antibody in cultured cells expressing wild-type or Rho A188 . The immunoprecipitates were washed three times with lysis buffer and boiled for 20 min at 68°C in buffer containing 5 mM EDTA, 2 mM dithiothreitol, 0.2% SDS, 0.5 mM GTP, and 0.5 GDP. GTP and GDP were separated on polyethylene-cellulose plates developed with 1 M KH2PO4 (pH 3.4) and measured by autoradiography.
Activated GTP-bound RhoA was also assayed by a different technique using Rhotekin (Rho binding domain). The GST-tagged fusion protein corresponding to residues 7-89 of Rhotekin was used to measure selectively active GTP-bound RhoA. Muscle cell lysates (100 g of protein) were incubated with glutathione-agarose slurry of Rhotekin at 4°C for 45 min. The beads were washed three times with the washing buffer containing (in mM) 50 Tris ⅐ HCl (pH 7.2), 150 NaCl, 10 MgCl2, and 0.1 PMSF, plus 10 g/ml of aprotinin, 10 g/ml of leupeptin, and 1% Triton X-100. GTP-bound RhoA was solubilized in Laemmli sample buffer and analyzed by 15% SDS-PAGE followed by Western blot analysis and chemiluminescence.
Assay for PLD activity. PLD activity was determined by the formation of the PLD-specific product, phosphatidylethanol (PEt), as described previously (27) Assay for Rho kinase activity. Rho kinase activity was determined by immunokinase assay in cell extracts as described previously (27) . Rho kinase was immunoprecipitated with Rho kinase antibody, and the immunoprecipitates were washed with phosphorylation buffer and incubated for 5 min on ice with 5 g of myelin basic protein. Kinase assays were initiated by the addition of 10 Ci of [␥-
32 P]ATP (3,000 Ci/mmol) and 20 M ATP, followed by incubation for 10 min at 37°C. [ 32 P]myelin basic protein was absorbed onto phosphocellulose discs, and free radioactivity was removed by repeated washings with 75 mM phosphoric acid. The amount of radioactivity on the discs was measured by liquid scintillation.
Immunoblot analysis of RhoA, Rho kinase, and phosphorylated MLC 20 . RhoA was measured in membrane and cytosolic fractions by Western blot analysis after treatment with ACh in the presence or absence of PKA and PKG activators. RhoA-Rho kinase association was determined by immunoblot in RhoA immunoprecipitates using Rho kinase antibody. Phosphorylated MLC 20 was determined by immunoblot analysis using a phospho-Ser 19 -specific antibody. The proteins were resolved by SDS-PAGE and electrophoretically transferred onto polyvinylidene difluoride membranes. Membranes were incubated for 12 h with appropriate antibody and then incubated for 1 h with a horseradish peroxidaseconjugated secondary antibody. The bands were identified by enhanced chemiluminescence.
Measurement of relaxation in dispersed smooth muscle cells. Inhibition of ACh-induced contraction (i.e., relaxation) by sodium nitroprusside (SNP) or VIP was expressed as the decrease in maximal cell contraction induced by 0.1 M ACh as described previously (24) (25) (26) . A 0.5-ml aliquot of cell suspension was added to 0.2 ml HEPES medium containing ACh alone and with SNP or VIP, and the reaction was terminated with 1% acrolein. Mean cell length of 50 muscle cells treated with various agents was measured by scanning micrometry and compared with the length of untreated muscle cells (mean control cell length: 116 Ϯ 3 m).
Materials. [ 32 P]orthophosphate was obtained from Amersham Pharmacia Biotech (Piscataway, NJ); collagenase and soybean trypsin inhibitor was from Worthington Biochemical (Freehold, NJ); Western blotting and chromatography material was from Bio-Rad Laboratories (Hercules, CA); RhoA antibody (Sc-119), MLC 20 phospho-antibody (Sc-12896), and Rho kinase antibody (Sc-5561) were from Santa Cruz Biotechnology (Santa Cruz, CA). All other chemicals were obtained from Sigma (St. Louis, MO). RhoA cDNA was a gift from Dr. Lee Slice, University of California (Los Angeles, CA).
RESULTS
Phosphorylation of
RhoA by PKG and PKA. In the basal state, RhoA is mainly present in the cytosol in inactive form bound to GDP and Rho guanine nucleotide dissociation inhibitor (GDI) and is translocated to the plasma membrane on activation by agonists (7, 17) . Treatment of freshly dispersed smooth muscle cells with ACh (0.1 M), SNP (1 M), or VIP (1 M) alone did not induce RhoA phosphorylation (Fig. 1 ). After treatment with ACh, however, both SNP and VIP induced RhoA phosphorylation, suggesting that the substrate is activated, membrane-bound RhoA (Fig. 1) . RhoA phosphorylation induced by SNP was concentration dependent and was abolished by the PKG inhibitor KT5823 but was not affected by PKA inhibitor myristoylated PKI (Figs. 2 and 3 ). RhoA phosphorylation induced by VIP, which activates both PKA and PKG in gastric smooth muscle cells (24) , was partly inhibited by KT5823 (55 Ϯ 6% inhibition) and myristoylated PKI (43 Ϯ 4% inhibition) and abolished by a combination of both kinase inhibitors (93 Ϯ 5% inhibition) (Fig. 3) .
Nonhydrolyzable membrane-permeable analogs of cGMP [8-(4-chlorophenylthio)guanosine 3Ј,5Ј-cyclic monophosphate; 8-pCPT-cGMP] and cAMP (5,6-dichloro- 1-␤-ribofuranosyl benzimidazole 3Ј,5Ј-cyclic monophosphothionate, Sp-isomer; cBIMPS) that selectively activate PKG and PKA, respectively, also induced phosphorylation of RhoA (Fig. 1) . Phosphorylation by 8-pCPT-cGMP was inhibited by KT5823 only, whereas phosphorylation by cBIMPS was inhibited by myristoylated PKI only (Fig. 3) . As previously shown by direct measurements of PKA and PKG activities in gastric smooth muscle cells, KT5823 and PKI, used at concentrations of 1 M and less, selectively inhibited PKG and PKA activity, respectively (24, 25) .
Phosphorylation of RhoA in cultured muscle cells overexpressing RhoA mutants. As shown in freshly dispersed smooth muscle cells, SNP and VIP induced RhoA phosphorylation in cultured smooth muscle cells overexpressing wild-type RhoA but only after stimulation with ACh (Fig. 4A) . However, both SNP and VIP induced phosphorylation of RhoA in the absence of ACh in permeabilized cultured smooth muscle cells overexpressing myc-tagged wild-type RhoA after treatment with GTP␥S or in cells overexpressing myctagged constitutively active Rho V14 (Fig. 4) . SNP and VIP did not induce RhoA phosphorylation in cells overexpressing dominate-negative Rho N19 (data not shown). Additional studies were done in cultured muscle cells overexpressing wild-type RhoA or Rho V14 . Phosphorylation was induced by 8-pCPT-cGMP or cBIMPS, and immunoprecipitation was performed separately with myc antibody and RhoA antibody. The results with RhoA antibody showed slightly greater phosphorylation indicative of endogenous RhoA (Fig.   4B) . The results implied that PKA and PKG preferentially phosphorylated active, membrane-bound RhoA. Inactive, cytosolic RhoA, bound to GDI at its COOH terminus, is probably protected from phosphorylation by PKA or PKG (17) .
Inhibition of RhoA activity by PKA and PKG. Acetylcholine-stimulated RhoA activity was inhibited by SNP (82 Ϯ 4%) and 8-pCPT-cGMP (92 Ϯ 5%) (Figs. 5 and 6 ). Inhibition by either agent was completely blocked by KT5823 but was not affected by myristoylated PKI. ACh-stimulated RhoA activity was inhibited also by cBIMPS (73 Ϯ 6%), and the inhibition was completely blocked by myristoylated PKI but was not affected by KT5823 (Fig. 6) . VIP inhibited ACh-stimulated RhoA activity by 94 Ϯ 6%; the inhibition was partly blocked by myristoylated PKI and KT5823 and was completely blocked by a combination of both kinase inhibitors, consistent with the ability of VIP to activate both PKA and PKG (Fig. 5) . Absence of PKA/PKG-dependent phosphorylation and inhibition of RhoA activity in phosphorylation sitedeficient Rho A188 . Previous studies (17, 18, 30, 31) have shown that RhoA can be phosphorylated in vitro by PKA and PKG at Ser 188 close to its COOH terminus and that mutation of this residue to Ala prevents phosphorylation by either kinase. In cells overexpressing myc-tagged wild-type RhoA, both SNP and VIP inhibited ACh-stimulated activation of RhoA. Neither SNP nor VIP had any effect on RhoA activation in cells overexpressing Rho A188 (Fig. 7A) . Similar results were obtained when RhoA activation was measured directly using the GST-tagged fusion protein Rhotekin (Fig.  7B) . The effect of SNP and VIP on RhoA phosphorylation was examined in cells overexpressing myc-tagged Rho
A188
. No phosphorylation was observed when immunoprecipitation was performed using myc antibody (Fig. 7C ). Significant phosphorylation of endogenous wild-type RhoA was observed when immunoprecipitation was performed using RhoA antibody (Fig. 7C) . The extent of phosphorylation was small when compared with phosphorylation obtained when wild-type RhoA was overexpressed. Results shown in Fig. 7 vivo and that phosphorylation at this site is essential for PKA-and PKG-dependent inactivation of RhoA.
Effects of PKA-and PKG-dependent phosphorylation on translocation of RhoA. Activation of RhoA requires translocation of inactive RhoA to the membrane in which p115RhoGEF mediates the exchange of GTP for GDP (7) (8) (9) . We examined whether phosphorylation by PKG and PKA accelerated translocation of membranebound RhoA back to the cytosol. Treatment of AChstimulated cells with SNP or VIP decreased the amount of membrane-bound RhoA, suggesting that RhoA phosphorylation accelerated the translocation of RhoA back to the cytosol (Fig. 8) . To examine further whether inhibition of RhoA activity could be distinguished from the effect of accelerated translocation of RhoA back to the cytosol, the effects of SNP and VIP on translocation were measured in cells overexpressing GTPase-resistant Rho V14 , which is predominantly membrane bound. Treatment of these cells with SNP and VIP decreased the amount of membrane-bound RhoA, suggesting that translocation was independent of inactivation (exchange of GDP for GTP) (Fig. 8) .
Phosphorylation probably decreases the binding of wild-type RhoA or Rho V14 to the membrane by increasing RhoA binding to GDI. The latter appears to extract RhoA from the membrane by competing with membrane lipids for binding to the geranylgeranylated COOH terminus of RhoA (2, 5, 12) . Consistent with this notion, SNP and VIP had no effect on the amount of membrane-bound RhoA in cells overexpressing phosphorylation site-deficient Rho A188 (Fig. 8) . Inhibition of ACh-stimulated RhoA/Rho kinase association by PKA and PKG. Translocation of RhoA back to the cytosol should prevent its association with and activation of two membrane-bound downstream effectors, Rho kinase and PLD. Treatment of dispersed smooth muscle cells with SNP or VIP decreased AChstimulated association of RhoA with Rho kinase (Fig.  9) . In cultured smooth muscle cells overexpressing Rho V14 , Rho kinase was predominantly associated with membrane-bound RhoA. Treatment of these cells with SNP or VIP decreased RhoA/Rho kinase association concurrently with translocation of RhoA back to the cytosol. Inhibition of RhoA/Rho kinase association by SNP and VIP was absent in cultured smooth muscle cells overexpressing phosphorylation site-deficient Rho A188 (Fig. 9) . Inhibition of ACh-stimulated Rho kinase and PLD activities by PKA and PKG. We (27) have previously shown that ACh and other contractile agonists stimulated Rho kinase and PLD activities and that both activities were strongly inhibited in cultured smooth muscle cells overexpressing dominate-negative Rho N19 . Here we show that ACh-stimulated Rho kinase and PLD activities in freshly dispersed smooth muscle cells were inhibited by SNP (86 Ϯ 4 and 81 Ϯ 7% inhibition, respectively), and the inhibition was completely reversed by KT5823 but not by myristoylated PKI (Fig. 10) . ACh-stimulated Rho kinase and PLD activities were inhibited also by VIP (78 Ϯ 6 and 74 Ϯ 4%, respectively). Inhibition was partly reversed by KT5823 (42 Ϯ 3 and 50 Ϯ 6%) and myristoylated PKI (33 Ϯ 5 and 42 Ϯ 3%) and completely reversed by a combination of both kinase inhibitors (Fig. 10) .
Both SNP and VIP inhibited Rho kinase activity in smooth muscle cells overexpressing constitutively active Rho V14 but had no effect in cells overexpressing phosphorylation site-deficient Rho A188 (Fig. 11) . The pattern of inhibition paralleled the translocation of RhoA to the cytosol and its dissociation from its targets in the membrane.
Inhibition of sustained MLC 20 phosphorylation and muscle contraction by PKA and PKG. Others (32, 35, 36) and we (27) have previously shown that sustained MLC 20 phosphorylation and smooth muscle contraction induced by contractile agonists including ACh were significantly inhibited by the Rho kinase inhibitor Y-27632 and/or by overexpression of dominate-negative Rho N19 . In the present study, Rho-dependent sustained MLC 20 phosphorylation and muscle contraction were measured 5 min after the addition of ACh, that is, after termination of the initial Rho-independent, Ca 2ϩ -dependent phase of contraction. Both SNP and VIP inhibited ACh-induced sustained muscle cell contraction in freshly dispersed smooth muscle cells (Fig. 12) . The inhibition of muscle contraction (i.e., relaxation) by SNP was selectively blocked by KT5823, whereas inhibition of contraction induced by VIP was partly blocked by KT5823 and myristoylated PKI and was completely blocked by a combination of both kinase inhibitors (Fig. 12) . ACh-induced sustained contraction was also inhibited by 8-pCPT-cGMP and cBIMPS. Inhibition by 8-pCPT-cGMP and cBIMPS was selectively blocked by KT5823 and myristoylated PKI, respectively (Fig. 13) .
To determine whether PKG and/or PKA could inhibit sustained MLC 20 (Fig. 14) . Complete inhibition of MLC 20 phosphorylation in cells overexpressing wild-type RhoA was accompanied by complete inhibition of RhoA and Rho kinase activities (Figs. 7 and 10) , precluding the involvement of mechanisms downstream of RhoA. However, partial inhibition by PKG and PKA in muscle cells overexpressing Rho A188 suggested the existence of a subsidiary inhib- itory mechanism downstream of RhoA normally masked by upstream inactivation of RhoA.
DISCUSSION
The crucial role of RhoA in mediating sustained MLC 20 phosphorylation and muscle contraction has focused attention on the ability of PKA and/or PKG to induce relaxation by inactivating RhoA and/or RhoA-dependent downstream effectors (4, 30) . Two RhoA-dependent convergent pathways that lead to inhibition of MLC phosphatase and enhanced phosphorylation of MLC 20 have been characterized. The two major effectors within these pathways are the regulatory subunit of MLC phosphatase MYPT1 and the PKC-dependent inhibitor of MLC phosphatase CPI-17 (3, 6, 32, 35) . Here we show that, whereas RhoA is the main target of PKG and PKA, there exists a subsidiary target downstream of RhoA normally masked by inactivation of RhoA.
PKG and PKA induced relaxation by phosphorylating activated, membrane-bound RhoA and accelerating its inactivation (i.e., exchange of GDP for GTP) and its dissociation from membrane-bound substrates (i.e., translocation back to the cytosol). In cultured smooth muscle cells overexpressing GTPase-resistant Rho V14 , phosphorylated RhoA was translocated to the cytosol without GDP, GTP exchange implying that inactivation and translocation of RhoA were distinct processes. In cells overexpressing phosphorylation site-deficient Rho A188 , ACh-stimulated Rho kinase activity and MLC 20 phosphorylation were similar to those in cells overexpressing wild-type RhoA. PKA and PKG abolished Rho kinase activity and MLC 20 phosphorylation in cells overexpressing wild-type RhoA, but they had little or no effect on Rho kinase activity in cells overexpressing Rho A188 , yet they partly inhibited MLC 20 phosphorylation. The partial inhibition of MLC 20 phosphorylation suggested the existence of an independent inhibitory mechanism downstream of RhoA normally masked in cells expressing wild-type RhoA by PKAand PKG-dependent phosphorylation and inactivation of RhoA (29, 33) .
These results differ from those of Sauzeau et al. (30) , who used a different experimental approach in which endogenous RhoA was not activated by agonists but was added exogenously. In these experiments, both exogenous RhoA and Rho A188 induced contraction in permeabilized vascular muscle strips, but only contraction induced by RhoA was inhibited by 8-Br-cGMP, suggesting the absence of mechanisms distal to RhoA. In contrast, Surks et al. (33) detected a PKG-depen- dent mechanism that could potentially function downstream of RhoA. They showed that blocking the interaction of the NH 2 -terminal leucine zipper sequence of PKG-I␣ with MYPT1 partly reversed the dephosphorylation of MLC 20 by 8-Br-cGMP, but they did not determine whether phosphorylation of RhoA contributed to dephosphorylation of MLC 20 .
The ability of RhoA phosphorylation to abolish MLC 20 phosphorylation precludes the necessity but does not eliminate the possibility for inactivation of targets downstream of RhoA by PKG or PKA. A likely candidate is the Rho kinase target, MYPT1, which binds selectively to PKG-I␣ but can be phosphorylated by PKA at Thr 853 (10, 33) . Phosphorylation by both kinases is assumed to enhance MLC phosphatase activity by uncoupling the catalytic subunit from membrane-bound MYPT1. The possibility that CPI-17, which is also located downstream of RhoA and is known to regulate MLC phosphatase activity, may, in turn, be regulated by PKG and/or PKA has not been explored.
It is not clear how phosphorylation of RhoA at Ser 188 accelerates its inactivation and translocation from the membrane. In the resting state, inactive GDP-bound RhoA is mainly present in the cytosol bound to GDI for which it has high affinity (7, 17) . GDI binds to RhoA via its geranylgeranylated COOH terminus, close to the site of phosphorylation (Ser 188 ) by PKA and PKG (17) . Consequently, little or no phosphorylation by PKA or PKG was observed in the present study in the basal state. Inactivation of membrane-bound RhoA involves GTP hydrolysis and translocation of RhoA back to the cytosol via a noncatalytic association with GDI; the latter appears to compete with membrane phospholipids for binding to inactivated RhoA (5, 17) . Though a distinct process, translocation of RhoA back to the cytosol was tantamount to inactivation, since it diverted RhoA from its membrane-bound substrates, chiefly, Rho kinase and PLD. It is possible that other components involved in the process of inactivation or translocation are susceptible to regulatory phosphorylation by PKG and PKA. Phosphorylation of GDI, a known substrate for PKG, is reported to stabilize the inactive Rho-GDI complex in the cytosol (2) .
In summary, this study shows that both PKG and PKA act preferentially on RhoA to inhibit sustained MLC 20 phosphorylation and muscle contraction. Both kinases phosphorylate RhoA, causing its prompt inactivation and translocation back to the cytosol away from its membrane-bound substrates, Rho kinase and PLD. The two pathways, Rho kinase/MYPT1 and PLD/ PKC/CPI-17, that converge to inhibit MLC phospha- tase are blocked, resulting in dephosphorylation of MLC 20 and muscle relaxation. The direct inactivation of RhoA masks a possible action of PKG and PKA on targets downstream of RhoA.
